XENT News and Press, Intersect ENT Inc. From 07/08/20

According to informed sources, Medtronic (NYSE: MDT ) has made an offer for sinus implant developer Intersect ENT  (NASDAQ: XENT ). More news on: Medtronic plc, Intersect ENT, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition news, Read more ...

Analysis Also Confirms Treatment with PROPEL Provides Improved Patient Outcomes Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a United Kingdom-based independent analysis mea...

Intersect ENT®, Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved SINUVA® (mometasone furoate) Sinus Implant for transitional pass-th...

Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference. The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m. CDT. To access the webcast, go to the "In...

Image source: The Motley Fool. Intersect ENT   (NASDAQ: XENT) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading

Intersect ENT, Inc. (XENT) Q1 2020 Earnings Conference Call May 11, 2020 16:30 PM ET Company Participants Tom West - President and Chief Executive Officer Richard Meier - Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMor...

Intersect ENT (NASDAQ: XENT ): Q1 GAAP EPS of -$0.54 misses by $0.08 . More news on: Intersect ENT, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Overview Revenue of $19.8 million in the first q...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management Company L.P. (“Deerfield...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30 p.m. ET on Monday, May 11, 2020. ...